Taxonomy

Novartis Secures $1.3B Deal for CMT Treatment CKD-510

Novartis is making significant strides in the field of Charcot-Marie-Tooth

Read More

Therapeutic Inactivation of CMT2 Disease Alleles with CRISPR

New technologies in gene editing such as CRISPR/Cas9 present a

Read More

CMTA Announces Participation in Seed Extension Round for Armatus Bio for Novel CMT1A Gene Therapy

First Investment from CMTA’s New Venture Philanthropy Arm The Charcot-Marie-Tooth

Read More

CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced

Read More

October 2023 Community Statement from Novartis

“The CMTA welcomes this community update from Novartis and applauds

Read More

CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28

Read More

Understanding Charcot-Marie-Tooth Disease in Children

This CMT awareness month, the CMTA’s Chief Research Officer, Katherine

Read More

Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant

New York, NY – September 12, 2023 — The Muscular

Read More

CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program

The Charcot-Marie-Tooth Association July 17 hailed the news that global

Read More

Development of Treatments for CMT2D

Professor Robert Burgess and his team at The Jackson Laboratory

Read More